Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition , and the Impact of Events Scale-Revised

Gnanavel, Sundar; Robert, Ruby Stella

doi:10.1378/chest.13-1691

Cited by 47 publications

(41 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Delirium is defined as a serious disturbance of cognition and consciousness by medical illnesses or neurologic causes by DSM-V criteria [1][2][3] and occurs in up to 30-80% of patients in the intensive care unit (ICU) [4][5][6][7]. The clinical presentation of delirium is often characterized by acute onset, an altered level of consciousness, a fluctuating course, and a global impairment of cognitive functioning.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Low-Dose Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Kim

Cho

et al. 2019

JCM

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy of short-term low-dose quetiapine for delirium prevention in critically ill patients. Methods: In this prospective, a single-center, randomized, double-blind, placebo-controlled trial, adult patients who were admitted from July 2015 to July 2017 to a medical intensive care unit (ICU) of a tertiary teaching hospital affiliated to Seoul National University were included. Quetiapine (12.5 mg or 25 mg oral at night; N = 16) or placebo (N = 21) was administered according to randomization until ICU discharge or the 10th ICU day. The primary endpoint was the incidence of delirium within the first 10 ICU days. Secondary endpoints included the rate of positive Confusion Assessment Method for the ICU (CAM-ICU) (the number of positive CAM-ICU counts/the number of total CAM-ICU counts), delirium duration, successful extubation, and overall mortality. Result: The incidence of delirium during the 10 days after ICU admission was 46.7% (7/15) in the quetiapine group and 55.0% (11/20) in the placebo group (p = 0.442). In the quetiapine group, the rate of positive CAM-ICU was significantly lower than in the placebo group (14.4% vs. 37.4%, p = 0.048), delirium duration during the study period was significantly shorter (0.28 day vs. 1.83 days, p = 0.018), and more patients in the quetiapine than in the placebo group were weaned from mechanical ventilation successfully (84.6% vs. 47.1%, p = 0.040). Conclusions: Our study suggests that prophylactic use of low-dose quetiapine could be helpful for preventing delirium in critically ill patients. A further large-scale prospective study is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of Low-Dose Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Kim

Cho

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Patients with neuropsychiatric disorders usually presented various behavioral phenotypes, including inattention, hyperactivity and increased impulsivity in ADHD patients [28] and spontaneous recurrent seizures accompanied by distinct neurobiological alterations in epilepsy patients [29]. The core symptoms of ASD patients demonstrated social defects and repetitive behaviors, associated with cognitive and learning disabilities [30,31]. Examination of zebrafish in the adolescent period showed that the nomo1 mutant zebrafish exhibit autism-like characteristic behavior.…”

Section: Discussionmentioning

confidence: 99%

Loss-of-function of the NOMO1 Gene Causes Neuropsychiatric Disorder-related Phenotypes

Li¹,

Li²,

Lin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Clinical genome-wide analysis identified NOMO1 in human chromosome 16p13.11 as a candidate gene associated with neuropsychiatric disorders such as autism, schizophrenia and epilepsy. However, the important contributions underlying NOMO1 deficiency resulting in neuropsychiatric disorders is not understand, and the molecular and pathogenesis mechanisms of nomo1 gene are unclear. Therefore, it is necessary to construct animal models to systematically study the effects of nomo1 deficiency on neuropsychiatric system and explore pathogenic molecular mechanism of diseases.Methods: We developed a viable vertebrate model of loss-of-function of nomo1 using CRISPR/Cas9 and studied the characterization of nomo1 mutant zebrafish. Phenotypic research was performed in developing nomo1 mutant zebrafish, including morphological measurements, behavioral tests, and functional mechanism analyses.Results: The nomo1 loss-of-function zebrafish model accurately recapitulated key neuropsychiatric disorders traits. The mutant zebrafish showed decreased locomotion in the larval stage (7 dpf), increased spontaneous movement in infancy (15 dpf and 30 dpf), and social defects and repetitive behaviors in adolescence (2 mpf). More importantly, we demonstrated that these behavioral phenotypes stem from abnormal brain structure and neurotransmitter metabolism. Transcriptome analysis provided insights for studying the functional mechanism of nomo1 pathogenesis. Further results revealed that the neuroactive drug PTZ recovered the decreased locomotion phenotype in larval zebrafish, which provides functional basis for the exploration of drug sensitivity and intervention in behavioral phenotypes of nomo1 mutant zebrafish.Conclusion: This study firstly reveal the functional evidence that loss-of-function of nomo1 elicits neuropsychiatric disorders, and emphasize the relationship between nomo1 deficiency and neuropsychiatric disorders from the perspectives of behavioral phenotypes, brain development, and neurotransmitter metabolism.Limitation: The behavioral phenotype intervention of neuroactive drug in nomo1-/-zebrafish can be directly translated to the behavior of human associated diseases need further study.

show abstract

“…The scale contains the items most consistently associated with the depression symptomatology and has shown to have adequate diagnostic accuracy, sensitivity, specificity, and reliability. The GDS-15 had been reported to be an excellent public health tool for identifying depression in non-specialized settings, such as general ambulatorial service, given its reduced application time 12 . The scoring system of the GDS-15 is from 0 to 5 points, indicating a normal psychological status, 6 to 10 points indicating mild depression, and 11 to 15 points indicating severe depression 13 .…”

Section: /7mentioning

confidence: 99%

Prevalence of depressive symptoms and factors associated in the elderly of the city of Pelotas-RS

Heidemann

Vilela

Cunha

et al. 2019

PAJAR

View full text Add to dashboard Cite

AIM: The aim of this study was to evaluate the prevalence of depressive symptoms and factors associated in the elderly of the city of Pelotas, southern Brazil. METHODS: In this cross-sectional study, the variables of interest were investigated with instruments about the socio-economic profile, aspects of physical and professional activities, eating and sleeping habits. RESULTS: 312 elderly people were interviewed, with a prevalence of depressive symptoms of 30.5%. A higher prevalence of depressive symptoms were found in women, individuals older than 81 years, from the low class, living alone, physically inactive, and retired. In the adjusted analysis, the non-practice of physical activity, low sleep quality, and daily sleeping medication were statistically associated with the outcome. In contradiction to the literature, our results refute the well-established gender roles that preconize that males are more affected by physical impairment, while the females are more affected by psychological and psychiatric disorders. CONCLUSIONS: In conclusion, it is important to identify the prevalence of depressive symptoms in a population commonly affected by other diseases. In addition, characteristics associated with depression were detected, which can help prevent or improve depression in this age group.

show abstract

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition , and the Impact of Events Scale-Revised

Cited by 47 publications

References 2 publications

Efficacy of Low-Dose Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Efficacy of Low-Dose Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Loss-of-function of the NOMO1 Gene Causes Neuropsychiatric Disorder-related Phenotypes

Prevalence of depressive symptoms and factors associated in the elderly of the city of Pelotas-RS

Contact Info

Product

Resources

About